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ABSTRACT
Objective: To describe the use of symptom-relieving
drugs (antimuscarinic drugs or duloxetine) before and
after surgery for urinary incontinence (UI); and for those
with use of antimuscarinic drugs or duloxetine before
surgery, to estimate the risk of being a postoperative
user, relative to those without use before surgery.
Design: A historical population-based cohort study.
Setting: Denmark.
Participants:Women ≥18 years with a first-time
surgical procedure for UI from the county of Funen,
Denmark between 1 January 1996 and 31 December
2006, extended to the Region of Southern Denmark from
1 January 2007 to the end of 2010. For these women,
data on redeemed prescriptions ±365 days of date of
surgery were extracted.
Main outcome measures: Effect of preoperative use
of antimuscarinic drugs or duloxetine on the risk of being
a postoperative user of these drugs.
Results: Of 2151 women with a first-time surgical
procedure for UI, 358 (16.6%) were preoperative users
of antimuscarinic drugs or duloxetine and 1793 were
not (83.4%). A total of 110 (30.7%) of the preoperative
users also redeemed prescriptions for these drugs within
0–60 days after surgery, and 152 (42.5%) of the
preoperative users redeemed prescriptions for these
drugs within 61–365 days after surgery. Among
preoperative non-users, 25 (1.4%) and 145 (8.1%)
redeemed prescriptions within 0–60 and 61–365 days
after surgery, respectively. Presurgery exposure to
antimuscarinic drugs or duloxetine was a strong risk
factor of postoperative drug use, both within 0–60 days
(adjusted OR=33.0, 95% CI 20.0 to 54.7) and
61–365 days (OR=7.2, 95% CI 5.4 to 9.6).
Conclusions: A substantial number of women will
continue to be prescribed symptom-relieving drugs after
surgery for UI within a year of follow-up. Only a minority
of preoperative non-users initiated usage of symptom-
relieving drugs after surgery. Compared with other
factors included in the regression model, preoperative
use of antimuscarinic drugs or duloxetine was the
strongest risk factor for postoperative use.
INTRODUCTION
Urinary incontinence (UI) is a very prevalent
disorder among women,1 and a wide array of
options for clinical managements exists.
Current best practice is a stepwise strategy
moving from conservative treatments such as
behavioural alteration, pelvic ﬂoor muscle
training and weight loss to pharmacological
treatment and, in selected cases, surgery.2
There are different pharmacological
options to relieve the symptoms of UI, includ-
ing antimuscarinic drugs and duloxetine.
Antimuscarinic drugs remain the mainstay
in the treatment of urgency UI, mixed UI as
well as the overactive bladder syndrome.3
Antimuscarinics reversibly block muscarinic
receptors in the bladder wall, acting primarily
by increasing bladder capacity rather than by
ablating detrusor overactivity. Although the
site of action has been thought to be M2 and
M3 receptors in detrusor smooth muscle
during contraction, there is growing evidence
that the therapeutic response might also be
the result of antagonist effects on muscarinic
receptors on afferent neurons4 as well as
central modulation. Duloxetine, a selective
serotonin-reuptake and norepinephrine-
reuptake inhibitor, is predominantly used as
an antidepressant, but has also been licensed
in some European countries for stress UI.
Presumably duloxetine acts by central modu-
lations, causing an increase in the urethral
sphincter tone.5
Strengths and limitations of this study
▪ A population-based study.
▪ In total 2151 women included.
▪ High quality of data sources and complete infor-
mation in the follow-up period for all included
women.
▪ Adjustment for several factors: age, procedure
type, preoperative oestrogen use, comorbidity,
educational level and personal annual income.
▪ Redeemed prescriptions were used as a proxy
for drug use.
▪ No data on type of urinary incontinence or uro-
dynamic studies.
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During the last decades, the surgical treatments of UI
in women have improved with the introduction of min-
imally invasive suburethral sling procedures for UI,6–8
submucosal intraurethal injections of bulking agents9
and intravesical injections of botulinum toxin10; and the
number of surgeries for UI has been increasing as
well.11 12
Three small studies by Segal et al13 (n=98), Yoo and
Kim14 (n=84) and Barber et al15 (n=162) have shown
that nearly 40% of preoperative antimuscarinic drug
users continued the use after surgery for UI.
This topic is highly relevant in advising women who are
candidates for surgical treatment for UI, if the results
could be conﬁrmed in larger studies. Women being
counselled for incontinence surgery would be better
served with information on the likelihood of both having
to remain on drug use or having to start the use for other
lower urinary tract symptoms following their procedure;
therefore, the purpose of this study was to assess the use
of symptom-relieving drugs before and after surgery for
UI in a larger population and to examine the possible
risk factors of postoperative drug use.
MATERIALS AND METHODS
Study population and settings
Data on all ﬁrst-time surgical procedures for UI in
women during the study period from 1 January 1996 to
31 December 2010 were retrieved from the Danish
National Patient Registry (NPR).16 The International
Classiﬁcation of Diseases (ICD) procedure codes for
data extraction are listed in online supplementary
appendix 1. The study population included women
≥18 years undergoing a ﬁrst-time surgical procedure for
UI in a hospital in the county of Funen (four hospitals),
Denmark between 1 January 1996 and 31 December
2006. For the period 2007 through 2010, the geograph-
ical area was extended to include all hospitals from the
Region of Southern Denmark (including Funen, a total
of 13 hospitals). The latter was due to a change in the
structure of healthcare in Denmark from counties to
regions in 2007. Women with concomitant or prior
surgery for pelvic organ prolapse were not excluded. In
women with more than one procedure code for UI in
the study period, the ﬁrst code was chosen as the
included procedure.
Data sources
Data for this study were retrieved from three Danish
registers: the NPR, the Odense University Pharmacoepi-
demiologic Database (OPED) and the Statistics
Denmark.
The NPR was established in 1977; it contains data on
discharges from public hospitals in Denmark. The com-
pleteness of recordings has been estimated to be
99.4%.17 The registry contains information about the
unique personal identiﬁcation number (CPN) assigned
to all Danish citizens, the dates of admission and
discharge, the surgical procedures performed, and up to
20 diagnoses for every discharge, classiﬁed according to
the ICD-8 (1977–1993) and ICD-10 (1994 and
onwards)18 19 as well as codes from the Danish classiﬁca-
tion system of surgical procedures.20
Information on relevant drugs (antimuscarinic drugs,
duloxetine and oestrogens) was retrieved within 1995–
2011 for the entire study population from OPED by
using CPN.
OPED contains person-identiﬁable data with complete
coverage on all computerised prescription reimburse-
ments from the County of Funen (population 2006:
479 000) from 1990 and from January 2007 onwards
extended to the whole Region of Southern Denmark
(population 1.2 million). The age and gender distribu-
tion of this population is very similar to that of the
Danish population as a whole (2006: 5.4 mio.), and the
prescription of drugs is very similar to the national
average.21 OPED is pharmacy based and captures all
reimbursed prescriptions.
Prescription reimbursements are offered as a part of
the National Health Service to all legal inhabitants of
Denmark and given independently of patient income.
Each record includes the CPN, the date of purchase, the
pharmacy, a full account of what has been purchased,
including brand name, Anatomical Therapeutic
Chemical (ATC) classiﬁcation code, total deﬁned daily
dose (DDD), dose unit and quantity. The database does
not contain information on indicative diagnoses, drugs
sold over the counter or drugs not reimbursed by the
county authority (mainly oral contraceptives, sedatives
and hypnotics). Data on the highest attained educa-
tional level and annual income were retrieved from the
Danish Integrated Database for Labor Market Research
at the Statistics of Denmark. This database contains
annually updated socioeconomic data for each Danish
citizen, mainly supplied by tax authorities, educational
institutions and employment services.22
Study drugs
Included drugs were antimuscarinic drugs (tolterodine
(ATC G04BD07), solifenacin (ATC G04BD08), trospium
chloride (ATC G04BD09), darifenacin (ATC G04BD10),
fesoterodine (ATC G04BD11), oxybutynin (ATC
G04BD04), ﬂavoxate (ATC G04BD02)), duloxetine
(ATC N06AX21) (only brand name Yentreve) and oes-
trogens (ATC G03C). Propiverine (ATC G04BD6) has
not been licensed in Denmark.
Exposed and unexposed cohorts
Exposed cohort: All women ≥18 years undergoing a ﬁrst-
time surgical procedure for UI between 1 January 1996
and 31 December 2010 in the county of Funen/Region
of Southern Denmark and having redeemed one or
more prescriptions for antimuscarinic drugs or duloxe-
tine for UI within 365 days preceding the date of surgery
(index date).
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Unexposed cohort: All women ≥18 years undergoing
a ﬁrst-time surgical procedure for UI between 1 January
1996 and 31 December 2010 in the county of Funen/
Region of Southern Denmark without having redeemed
similar prescriptions within the same time frame.
Outcome data
For exposed and unexposed women, the ﬁrst-time
outcome was the use of symptom-relieving drugs,
deﬁned as having redeemed at least one prescription for
antimuscarinic drugs or duloxetine within (1) 60 days
after the index date (short term postoperatively) and (2)
61–365 days after the index date (long term postopera-
tively). These outcomes were not mutually exclusive, that
is, a woman might be classiﬁed both as a short-term and
long-term user postoperatively.
Covariates
The use of symptom-relieving drugs might be affected
by age, type of procedure, use of oestrogen, comorbidity,
educational level, annual income and calendar time;
therefore, these variables were included in the analysis
as potential confounders.
Type of procedures: The types of UI surgery were divided
into four groups according to the surgical procedure
code: (1) mid-urethral sling procedures with transob-
turator route (toMUS), (2) mid-urethral sling proce-
dures with retropubic route (rpMUS), (3) bulking
procedures and (4) other types of UI surgeries.
Oestrogen: To adjust for preoperative oestrogen use,
women were divided into those who had redeemed at
least one prescription for oestrogens within 365 days
prior to surgery, and those who had no preoperative oes-
trogen use. Both systemic and local oestrogens were
included.
Comorbidity: Comorbidity was classiﬁed according to
the Charlson comorbidity index (CCI),23a well-known,
validated and widely used quantitative measure of
comorbid illness.24 25 It assigns different weights (1, 2, 3
and 6) to 19 different disease categories speciﬁed by
medical condition and severity (eg, diabetes, cardiovas-
cular diseases, chronic pulmonary, renal, liver and con-
nective tissue diseases). For each woman, the CCI was
computed based on her complete hospital discharge
history from the NPR since 1977. A categorised version
of the CCI with score values grouped were used: 0 (low),
1–2 (medium) and 3+ (high).26
Socioeconomic status: To measure socioeconomic status,
information on education and annual income for each
woman was retrieved. Education was categorised accord-
ing to the highest attained educational level as ‘Basic’
(basic school/high school education: 7–12 years of ﬁrst-
time, secondary and grammar-school education),
‘Secondary’ (vocational education, 10–12 years of educa-
tion) and ‘Higher’ (a university degree or an examin-
ation in another higher institution requiring on average
a total of 13 years or more).27
On the basis of quartiles of annual income for each
women at the year of her surgery, we categorised women
in low (1st quartile), medium (2nd and 3rd quartile)
and high income (4th quartile) recipients.
Statistical analysis
We describe in a ﬂow chart the use of symptom-relieving
drugs within the ﬁrst 365 days after surgery for the two
groups of users and non-users of drugs prior to surgery.
We also constructed contingency tables for the main
study variables, and computed the OR, with 95% CI.
To analyse the signiﬁcance of preoperative symptom-
relieving drug use as a risk factor of postoperative use
(short and long term), adjusted ORs were estimated by
means of multivariate logistic regression models.
Adjustment was made for age (18–39, 40–59, ≥60 years (ref-
erence)), type of procedures (toMUS (reference), rpMUS,
Bulking, others), education (basic (reference), second-
ary, higher), annual income (low (reference), middle,
high), comorbidity (CCI 0 (reference), CCI 1–2, CCI 3
+), calendar-year (1996–2006, 2007–2008 (reference),
2009–2010) and use of oestrogen within 365 days preced-
ing surgery (No (reference), Yes).
All analyses were performed using Stata Release V.12.0.
RESULTS
A total of 2151 women had a ﬁrst-time surgical proced-
ure for UI between 1 January 1996 and 31 December
2010 (2073 had solitary UI surgery, and 78 had concomi-
tant surgery for pelvic organ prolapse).
Of the 2151 women, 358 (16.6%) were exposed to
symptom-relieving drugs within 365 days before surgery,
and 1793 (83.4%) were not. The use of symptom-
relieving drugs within 365 days after surgery is detailed
in both these cohorts (ﬁgure 1).
Women having redeemed prescriptions for
symptom-relieving drugs before surgery (exposed)
Of the 358 women with prior drug use of antimuscarinic
drugs or duloxetine, 110 (30.7%) women redeemed pre-
scriptions for these drugs within 0–60 days after surgery,
and 98 of the 358 women (26.8%) did so within 61–
365 days after surgery (ﬁgure 1). On the other hand,
248 (69.3%) women did not redeem a prescription for
symptom-relieving drugs within 0–60 days after surgery,
and the majority of these women (192/358=53.6%) also
abstained from symptom-relieving drugs during the time
frame 61–365 days after surgery (ﬁgure 1). For the
exposed women, the number of redeemed prescriptions
was 1360 preoperatively (DDD 174.6 (SD±202)), post-
operatively 126 (DDD 32.3 (SD±63.5)) within 0–60 days
and 984 (DDD 140.4 (SD±234.3)) within 61–365 days.
Women with no usage of symptom-relieving drugs before
surgery (unexposed)
Only 25 of the 1793 (1.4%) women redeemed a ﬁrst-time
prescription for symptom-relieving drugs within 0–60 days
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after surgery, and these women typically continued
their use within 61–365 days after surgery (20 women;
ﬁgure 1). Of the 1793 women who did not redeem pre-
scription before surgery, 1768 (98.6%) women remained
non-users within 0–60 days after surgery, and the vast
majority of these women (1643/1793=91.6%) continued
as non-users also within 61–365 days after surgery
(ﬁgure 1). For the unexposed women, the number of
redeemed prescriptions postoperatively was 129 (DDD
0.8 (SD±8.8)) within 0–60 days, and 403 (DDD 11.9
(SD±54.8)) within 61–365 days.
The baseline characteristics of exposed and unex-
posed women are presented in table 1. The most com-
monly used procedures were rpMUS or toMUS. The
exposed women were more likely to have had a transob-
turator mid-urethral sling or a bulking agent injection
compared with unexposed women, where retropubic
mid-urethral sling was the preferred procedure. The
most commonly prescribed drugs prior to surgery were
solifenacin and tolterodine. Compared with unexposed
women, the exposed women tended to be older, to be
more frequent oestrogen-users, to have higher
comorbidity, a lower educational level and a lower
annual income.
Among women with prior drug use, the unadjusted
OR of being a short-term or long-term user of symptom-
relieving drugs after surgery was 31.1 (95% CI 19.9 to
49.4) and 8.4 (95% CI 6.4 to 11.0), respectively. The
adjusted OR of being a short-term or long-term user of
symptom-relieving drugs after surgery was 33.0 (95% CI
20.0 to 54.7) and 7.2 (95% CI 5.4 to 9.6), respectively.
The details from logistic regression models presented in
table 2 show the impact of each risk factor included.
The preoperative use of antimuscarinic drugs or duloxe-
tine was the absolutely strongest risk factor of post-
operative use (both short and long term); that is,
compared with preoperative drug use, no other factors
contributed considerably to the OR of being a short-
term or long-term postoperative user.
DISCUSSION
Among 2151 women undergoing ﬁrst-time surgery for
UI, less than 20% had redeemed prescriptions for anti-
muscarinic drugs or duloxetine prior to surgery, and
nearly 30% of these continued using the drugs within
2 months after surgery and typically stayed long-term
users. Among the women without drug use before
surgery, the vast majority continued to be non-users
after surgery, with fewer than 9% redeeming a ﬁrst-time
prescription of the drugs.
Our study has several strengths: (1) it is a population-
based study in the sense that it covers all the relevant
surgeries in a well-deﬁned geographic area in Denmark,
(2) The source of procedure has high coverage and val-
idity. The NPR records 99.4% of all discharges from hos-
pitals in Denmark, and the procedures in the NRP have
been validated showing a moderate-to-high quality of the
data with positive predictive values of 94–100%,28–30 (3)
the access to high quality data on prescriptions from the
OPED that are representative for the Danish popula-
tion,21 (4) information on several confounders such as
comorbidity and socioeconomic status, (5) complete
information in the follow-up period for all included
women, (6) outcome data on postoperative drug pre-
scriptions were obtained independently of exposure
assessment preventing differential misclassiﬁcation of
the outcome, and ﬁnally (7) the drugs and the surgical
procedures included in our study do not have other
indications than UI, which strongly limits the number of
alternative interpretations of our ﬁndings.
Our study also has limitations. Data on redeemed pre-
scription are only a surrogate for drug intake. However,
antimuscarinic drugs and especially duloxetine are
expensive drugs with signiﬁcant patient copayment, and
we ﬁnd it unlikely that these drugs to any major extent
would be bought and not consumed. We had no data on
patient symptomatology, that is, whether stress UI,
urgency UI, mixed UI or overactive bladder syndrome
was predominant, just as there were no available data on
Figure 1 Women (N=2151) with
first-time surgery for urinary
incontinence (UI) and their use of
symptom-relieving drugs for UI
(antimuscarinic drugs and
duloxetine) before and after
surgery for UI. Exposed women
had redeemed one or more
prescriptions of antimuscarinic
drugs or duloxetine within
365 days preceding the date of
surgery, and unexposed women
had not redeemed prescriptions
of antimuscarinic drugs or
duloxetine within 365 days
preceding the date of surgery.
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ﬁndings in urodynamic studies. The exposed cohort was
receiving symptom-relieving drugs, and thus these
women most likely had predominantly mixed UI,
whereas the unexposed women most likely had predom-
inantly stress UI. We were not able to control for
potential confounders such as body mass index, parity,
grade of concomitant cystocele, severity of UI symptoms,
intrinsic sphincter deﬁciency or menopausal status,
which are well-known risk factors for persistent UI after
surgery for UI.31–35 One might speculate whether dur-
ation of time with UI symptoms and preoperative conser-
vative treatment could impact our estimates of
postoperative drug use, as women in the exposed cohort
could have longer disease duration before surgery than
women in the unexposed cohort. This could be due to
more extensive preoperative evaluations including uro-
dynamic studies, as well as waiting time to evaluate the
effect of drug treatment in the exposed cohort.
However, to our knowledge, no studies have indicated
that disease duration or conservative treatment of UI is a
risk factor for postoperative drug use, and therefore we
do not believe our estimates of postoperative drug use
are inﬂuenced by duration of time with UI symptoms.
The currently available drugs for UI are expensive and
have many side effects,36 and the long-term persistence
of the use of antimuscarinic drugs as well as duloxetine
is low (without regarding surgery).37–39 All the latter
may contribute to the cessation of the drugs, and thus a
reduction in the drug usage may not be explained
entirely by the surgery. The reasons for cessation of drug
use after surgery can be inﬂuenced by other factors as
well. For example, misinterpretation of symptoms/inves-
tigations may lead to treatment of stress UI with
symptom-relieving drugs.
The risk of initiating medical treatment after surgery for
UI (based on de novo surgery) is small but well known.40
There was a low rate of concomitant pelvic recon-
structive surgery, as was expected given the current prac-
tice in Scandinavia with a conservative approach of
addressing the predominant problem of either pelvic
organ prolapse or UI in sequential surgery.41 Age was
higher among the exposed than among the unexposed
women, and therefore, expectedly, we found a higher
proportion of women with high comorbidity in the
exposed group—and furthermore, not surprisingly, a
higher proportion of Bulking procedures among
exposed women as this procedure is often preferred in
women with high comorbidity.
To our knowledge, this is the largest study to address
changes in the use of symptom-relieving drugs in rela-
tion to surgery for UI, and having a large number of
possible risk factors of postoperative use. Our results in
this larger population are consistent with the previous
smaller studies.13–15
Compared with the previous studies, our study
included a larger number of women with UI surgery,
estimated the risk of postoperatively symptom-relieving
drug use with adjustment for a number of relevant cov-
ariates, and assessed the risk of both short-term and
long-term use. Our study also showed that educational
level, personal income and type of procedure did not
seem to inﬂuence the risk of postoperative drug use.
High comorbidity was found to signiﬁcantly increase the
Table 1 Baseline characteristics of all included women
(N=2151) having first-time surgery for urinary incontinence
in Denmark, 1996–2010
Exposed
n=358
(16.6%)
Unexposed
n=1793
(83.4%)
Mean age (±SD), years
(At time of first UI
surgery)
60.9 (±12.7) 54.5 (±12.6)
Age groups n (%)
18–39 13 (3.6) 199 (11.1)
40–59 151 (42.2) 956 (53.3)
60– 194 (54.2) 638 (35.6)
Procedures n (%)
rpMUS 73 (20.4) 602 (33.6)
toMUS 172 (48.0) 800 (44.6)
Bulking 101 (28.2) 259 (14.4)
Others 12 (3.4) 132 (7.4)
Concomitant prolapse
surgery n (%)
11 (3.1) 67 (3.7)
Symptom-relieving medications n (%)*
Solifenacin 176 (49.2) –
Tolterodine 84 (23.5) –
Fesoterodine 63 (17.6) –
Trospium chloride 32 (8.9) –
Oxybutynin 29 (8.1) –
Darifenacin 14 (3.9) –
Emepronium 6 (1.7) –
Duloxetine 6 (1.7) –
Oestrogen users n (%)†
No 135 (37.7) 1073 (59.8)
Yes 223 (62.3) 720 (40.2)
Comorbidity (CCI) n (%)
0 214 (59.8) 1298 (72.3)
1–2 107 (29.9) 413 (23.0)
3+ 37 (10.3) 82 (4.6)
Educational level n (%)‡
Basic 178 (51.7) 739 (41.8)
Secondary 125 (36.3) 645 (36.5)
Higher 41 (11.9) 383 (21.7)
Annual income n (%)
Low (1st quartile) 100 (27.9) 437 (24.4)
Middle (2nd–3rd quartile) 206 (57.6) 871 (48.6)
High (4th quartile) 52 (14.5) 485 (27.0)
Year of surgery n (%)
1996–2006 50 (14.0) 409 (22.8)
2007–2008 118 (33.0) 673 (37.5)
2009–2010 190 (53.0) 711 (39.7)
*Does not sum up to 100%. Some women redeemed more than
one type of the drugs during the time period.
†Women with at least one redeemed prescription of oestrogen
within 365 preceding surgery.
‡Unknown highest attained educational level: 40 women.
CCI, Charlson comorbidity index; rpMUS, retropubic mid-urethral
sling; toMUS, transobturator mid-urethral sling; UI, urinary
incontinence.
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risk, but it did not inﬂuence the estimates as much as
the preoperative drug use, which was the strongest risk
factor of postoperative drug use. More studies are
needed to examine the possible impact of body mass
index, menopausal status, the predominant type of
incontinence and the relationship between time from
diagnosis of UI to performed surgery and the following
probability of receiving symptom-relieving drugs.
In conclusion, we found that a substantial number of
women will continue to be prescribed symptom-relieving
drugs after surgery for UI within a year of follow-up. Only
a minority (8.1%) of preoperative non-users initiated
usage of symptom-relieving drugs after surgery. Compared
with preoperative drug use, no other factors in the regres-
sion model contributed considerably to the OR of being a
short-term or long-term postoperative user of symptom-
relieving drugs. Counselling women prior to UI surgery
should therefore include information on the high risk of
continuing use after surgery for preoperative users of
symptom-relieving drugs, and preoperative non-users have
a risk—although it is low—of becoming a user.
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Table 2 Risk factors of postoperative use of antimuscarinic drugs/duloxetine
Postoperative
non-use Postopetative short-term use
Postoperative
non-use
Postoperative long-term
use
Number Number OR (95% CI) Number Number OR (95% CI)
Preoperative use
No 1768 25 reference 1648 145 reference
Yes 248 110 33.0 (20.0 to 54.7) 145 152 7.2 (5.4 to 9.6)
Age group
18–39 209 3 0.3 (0.1 to 1.4) 204 8 0.3 (0.1 to 0.7)
40–59 1063 44 0.6 (0.3 to 0.9) 999 108 0.6 (0.4 to 0.8)
60– 744 88 reference 651 181 reference
Procedure
rpMUS 659 16 0.6 (0.3 to 1.2) 612 63 0.6 (0.4 to 0.9)
toMUS 894 78 reference 842 130 reference
Bulking 322 38 1.2 (0.7 to 2.0) 262 98 0.5 (0.3 to 0.7)
Others 141 3 0.5 (0.1 to 2.6) 138 6 0.3 (0.1 to 1.0)
Preoperative use of oestrogen*
No 1159 49 reference 1090 118 reference
Yes 857 86 0.8 (0.5 to 1.4) 764 179 1.0 (0.7 to 1.4)
Comorbidity (CCI)
0 1442 70 reference 1352 160 reference
1–2 467 53 1.5 (0.9 to 2.4) 419 101 1.5 (1.1 to 2.0)
3+ 107 12 0.9 (0.4 to 1.9) 83 36 1.9 (1.2 to 3.2)
Educational level†
Basic 846 71 reference 761 156 reference
Secondary 727 43 0.9 (0.6 to 1.5) 674 96 0.9 (0.6 to 1.2)
Higher 407 17 1.1 (0.6 to 2.3) 385 39 0.8 (0.5 to 1.3)
Annual income
Low 489 48 reference 442 95 reference
Middle 1010 67 0.7 (0.4 to 1.2) 929 148 0.9 (0.6 to 1.2)
High 517 20 0.9 (0.4 to 1.8) 483 54 1.1 (0.7 to 1.9)
Year of surgery
1996–2006 448 11 0.7 (0.3 to 1.7) 427 32 0.5 (0.3 to 0.9)
2007–2008 739 52 reference 675 116 reference
2009–2010 829 72 0.9 (0.6 to 1.4) 752 149 1.0 (0.7 to 1.4)
Results from multivariate logistic regression models in (1) short term (0–60 days after surgery) and (2) long term (61–356 days after surgery).
*Women with at least one redeemed prescription of oestrogen within 365 preceding surgery.
†Unknown highest attained educational level: 40 women.
CCI, Charlson comorbidity index; rpMUS, retropubic mid-urethral sling; toMUS, transobturator mid-urethral sling.
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